In the latest escalation of the long-running dispute, up to 1270 workers will walk out of CSL’s Melbourne office, expressing anger at management’s response to union members voting down the company’s ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Should you be buying the dip? Let's find out. CSL shares crashed 39% during 2025 to $172.65 as management slashed revenue and profit growth guidance, signalling that the biotherapeutics giant's next ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

Nov 18 (Reuters) - Australian biotech firm CSL (CSL.AX), opens new tab said on Tuesday it would invest $1.5 billion in the U.S. to manufacture plasma-derived therapies, in a move to expand its ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

CSL Seqirus, the vaccine unit of Australian biotech CSL, has signed a pact to provide Saudi Arabia with cell-based influenza shots and help establish its production in-country. The move forms part of ...

CSL Ltd. plunged to the lowest in almost seven years after Australia’s biggest drugmaker postponed plans to spin off its vaccines business, as falling US flu immunizations deepen concern over a ...

View post: Walmart's Magnetic Phone Car Charger Is Now on Sale for Just $16, and It 'Works Perfectly' The Ultimate Driving Machine never stopped evolving, and the BMW M4 CSL is one of the best modern ...

The exit delivers a 3.5x return CSL has grown around 20% annually ECI first invested in CSL in 2020 ECI Partners has exited CSL, a critical IoT connectivity business, into a continuation fund, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Australian biotechnology ...

Joy Linton, Chief Financial Officer of Australia's biotech company CSL talks about the company's restructuring, the impact of U.S. tariffs and currency volatility risks. Got a confidential news tip?